Estimating the proportion of treatment effect explained by a surrogate marker.
暂无分享,去创建一个
V De Gruttola | T R Fleming | D. Lin | D. Lin | T. Fleming | V. De Gruttola | V. Gruttola | D Y Lin
[1] M. Wulfsohn,et al. Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .
[2] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[3] N. Nagelkerke,et al. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. , 1994, Statistics in medicine.
[4] T. Fleming,et al. Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.
[5] B. Graubard,et al. Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.
[6] L. J. Wei,et al. The Robust Inference for the Cox Proportional Hazards Model , 1989 .
[7] W. Guerra. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter , 1991 .
[8] John D. Kalbfleisch,et al. Misspecified proportional hazard models , 1986 .
[9] Kaizhai Shen,et al. CD4 , 1990 .
[10] D Y Lin,et al. MULCOX2: a general computer program for the Cox regression analysis of multivariate failure time data. , 1993, Computer methods and programs in biomedicine.
[11] Robert Schooley,et al. CD4+ Lymphocytes Are an Incomplete Surrogate Marker for Clinical Progression in Persons with Asymptomatic HIV Infection Taking Zidovudine , 1993, Annals of Internal Medicine.
[12] H. White. Maximum Likelihood Estimation of Misspecified Models , 1982 .
[13] L. J. Wei,et al. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .
[14] D Y Lin,et al. MULCOX: a computer program for the Cox regression analysis of multiple failure time variables. , 1990, Computer methods and programs in biomedicine.
[15] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[16] S W Lagakos,et al. Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .
[17] Nils Lid Hjort,et al. On inference in parametric survival data models , 1992 .
[18] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[19] E. C. Fieller. The Biological Standardization of Insulin , 1940 .